In summary, previous work has implicated the β-cell EP3 receptor as a potential target for T2D therapeutics, but our results with the C57Bl/6J LeptinOb mouse model suggest that the contribution of EP3 to β-cell compensation and function is much more nuanced. Here, PTGER3 is linked to type 2 diabetes mellitus.